Clinical Applications of Immunotherapy for Recurrent Glioblastoma in Adults.
Clinical Applications of Immunotherapy for Recurrent Glioblastoma in Adults.
复制标题
作者：
复发性胶质母细胞瘤（rGBM）的治疗选择很少。免疫疗法增强免疫系统对抗肿瘤生长，为治疗常规治疗后复发的GBM提供了新的希望。本文综述了近年来rGBM免疫治疗的临床研究，包括免疫检查点阻断、溶瘤病毒治疗、嵌合抗原受体（CAR）T细胞治疗、肿瘤疫苗和抗体结合毒素等。文献检索于2023年2月结束。这篇免疫治疗综述全面概述了治疗进展、每种策略的局限性、正在进行的机会以及与生存的初步相关性，以支持临床决策并指导未来的研究工作。胶质母细胞瘤（GBM）是成人中最常见的恶性原发性脑肿瘤。尽管有标准的治疗，包括切除和放化疗，复发几乎是不可避免的。目前复发性胶质母细胞瘤（rGBM）的治疗正在迅速发展，针对原发性GBM的新兴疗法通常首先在rGBM中进行测试，以证明安全性和可行性，近年来，主要是免疫疗法的形式。本文综述了rGBM免疫治疗的临床研究进展，包括免疫检查点阻断、溶瘤病毒治疗、嵌合抗原受体（CAR）T细胞治疗、肿瘤疫苗和免疫毒素等。三位独立评审员涵盖了2000年至2022年期间在各种在线数据库中发表的文献。一般来说，免疫疗法在rGBM中的疗效仍然不确定，并且仅限于患者的子集/小队列，尽管在早期临床试验中证明了可行性。然而，在理解可能阻止rGBM患者对免疫疗法作出反应的机制以及开发新方法/组合策略方面已经取得了相当大的进展，这些方法/组合策略可能会激发人们对免疫疗法在这种毁灭性疾病中的效用的乐观态度。继续试验是必要的，以进一步评估最佳的治疗途径，并确定哪些治疗可能有利于每个患者。
There are few established treatment options for recurrent glioblastoma (rGBM). Immunotherapy, which potentiates the immune system to counter tumor growth, offers new hope for treating GBM that has relapsed after conventional therapies. The aim of this literature review is to summarize recent clinical studies of immunotherapy for rGBM, including that of immune checkpoint blockade, oncolytic virotherapy, chimeric antigen receptor (CAR) T-cell therapy, cancer vaccine and antibody-conjugated toxin. The literature search was concluded in February 2023. This review of immunotherapies provides a comprehensive overview of treatment advances, limitations in each strategy, ongoing opportunities, and preliminary correlates to survival, in order to support clinical decision-making and guide future research endeavors. Glioblastoma (GBM) is the most common malignant primary brain tumor in adults. Despite standard therapies, including resection and chemoradiation, recurrence is virtually inevitable. Current treatment for recurrent glioblastoma (rGBM) is rapidly evolving, and emerging therapies aimed at targeting primary GBM are often first tested in rGBM to demonstrate safety and feasibility, which, in recent years, has primarily been in the form of immunotherapy. The purpose of this review is to highlight progress in clinical trials of immunotherapy for rGBM, including immune checkpoint blockade, oncolytic virotherapy, chimeric antigen receptor (CAR) T-cell therapy, cancer vaccine and immunotoxins. Three independent reviewers covered literature, published between the years 2000 and 2022, in various online databases. In general, the efficacy of immunotherapy in rGBM remains uncertain, and is limited to subsets/small cohorts of patients, despite demonstrating feasibility in early-stage clinical trials. However, considerable progress has been made in understanding the mechanisms that may preclude rGBM patients from responding to immunotherapy, as well as in developing new approaches/combination strategies that may inspire optimism for the utility of immunotherapy in this devastating disease. Continued trials are necessary to further assess the best therapeutic avenues and ascertain which treatments might benefit each patient individually.
登录
查看更多内容
影响因子：
5.2
作者：
Anghileri E;Patanè M;Di Ianni N;Sambruni I;Maffezzini M;Milani M;Maddaloni L;Pollo B;Eoli M;Pellegatta S
通讯作者：
Pellegatta S
影响因子：
5.2
作者：
Cao, Toni Q.;Wainwright, Derek A.;Lee-Chang, Catalina;Miska, Jason;Sonabend, Adam M.;Heimberger, Amy B.;Lukas, Rimas, V
通讯作者：
Lukas, Rimas, V
影响因子：
64.8
作者：
Capper D;Jones DTW;Sill M;Hovestadt V;Schrimpf D;Sturm D;Koelsche C;Sahm F;Chavez L;Reuss DE;Kratz A;Wefers AK;Huang K;Pajtler KW;Schweizer L;Stichel D;Olar A;Engel NW;Lindenberg K;Harter PN;Braczynski AK;Plate KH;Dohmen H;Garvalov BK;Coras R;Hölsken A;Hewer E;Bewerunge-Hudler M;Schick M;Fischer R;Beschorner R;Schittenhelm J;Staszewski O;Wani K;Varlet P;Pages M;Temming P;Lohmann D;Selt F;Witt H;Milde T;Witt O;Aronica E;Giangaspero F;Rushing E;Scheurlen W;Geisenberger C;Rodriguez FJ;Becker A;Preusser M;Haberler C;Bjerkvig R;Cryan J;Farrell M;Deckert M;Hench J;Frank S;Serrano J;Kannan K;Tsirigos A;Brück W;Hofer S;Brehmer S;Seiz-Rosenhagen M;Hänggi D;Hans V;Rozsnoki S;Hansford JR;Kohlhof P;Kristensen BW;Lechner M;Lopes B;Mawrin C;Ketter R;Kulozik A;Khatib Z;Heppner F;Koch A;Jouvet A;Keohane C;Mühleisen H;Mueller W;Pohl U;Prinz M;Benner A;Zapatka M;Gottardo NG;Driever PH;Kramm CM;Müller HL;Rutkowski S;von Hoff K;Frühwald MC;Gnekow A;Fleischhack G;Tippelt S;Calaminus G;Monoranu CM;Perry A;Jones C;Jacques TS;Radlwimmer B;Gessi M;Pietsch T;Schramm J;Schackert G;Westphal M;Reifenberger G;Wesseling P;Weller M;Collins VP;Blümcke I;Bendszus M;Debus J;Huang A;Jabado N;Northcott PA;Paulus W;Gajjar A;Robinson GW;Taylor MD;Jaunmuktane Z;Ryzhova M;Platten M;Unterberg A;Wick W;Karajannis MA;Mittelbronn M;Acker T;Hartmann C;Aldape K;Schüller U;Buslei R;Lichter P;Kool M;Herold-Mende C;Ellison DW;Hasselblatt M;Snuderl M;Brandner S;Korshunov A;von Deimling A;Pfister SM
通讯作者：
Pfister SM
影响因子：
17.1
作者：
Brown MC;Holl EK;Boczkowski D;Dobrikova E;Mosaheb M;Chandramohan V;Bigner DD;Gromeier M;Nair SK
通讯作者：
Nair SK
影响因子：
15.9
作者：
Bloch, Orin;Crane, Courtney A.;Parsa, Andrew T.
通讯作者：
Parsa, Andrew T.